

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia

Anne-Sophie Chretien^{1,2}, Cyril Fauriat^{1,2}, Florence Orlanducci², Jerome Rey³, Gaele Bouvier Borg⁴, Emmanuel Gautherot⁴, Samuel Granjeaud⁵, Clemence Demerle^{1,2}, Jean-François Hamel⁶, Adelheid Cerwenka⁷, Elke Pogge von Strandmann^{8,15}, Norbert Ifrah⁹, Catherine Lacombe¹⁰, Pascale Cornillet-Lefebvre¹¹, Jacques Delaunay¹², Antoine Toubert¹³, Christine Arnoulet^{1,14}, Norbert Vey^{1,3} and Daniel Olive^{1,2}

¹Team Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France

²Immunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France

³Hematology Department, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France

⁴Beckman Coulter Immunotech, Marseille, France

⁵Systems Biology Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France

⁶Biostatistics and Methodology Department, CHU Angers, Angers, France

⁷Innate Immunity Group, German Cancer Research Center, Heidelberg, Germany

⁸Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany

⁹Hematology Department, CHU Angers, Angers, France

¹⁰GOELAMStheque, FILO French Innovative Leukemia Organization, Cochin Hospital, APHP, Paris, France

¹¹Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Reims, Reims, France

¹²Service d'Hématologie, Centre Catherine de Sienne, Nantes, France

¹³INSERM UMRS-1160, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Immunology and Histocompatibility Department, Hôpital Saint-Louis, APHP, Paris, France

¹⁴Biopathology Department, Institut Paoli Calmettes, Marseille, France

¹⁵Clinic for Hematology, Oncology and Immunology, Experimental Tumor Research, Center for Tumor Biology and Immunology, Philipps University, Marburg, Germany

Published: September 10, 2019

Copyright: Chretien et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Additional information has been added to the Funding section. The complete and updated Funding information is shown below:

FUNDING

This work has been financially supported by the INCa, the SIRIC Marseille (grant INCa-DGOS-INSERM 6038), the Cancéropôle PACA (grants K_CyTOF 2014 and AML_CyTOF 2016 for J.A.N.), the GS IBiSA and the Agence Nationale de la Recherche (PHENOMIN project for MM HL and EG). The team "Immunity and Cancer" was labeled "Equipe FRM DEQ 201 40329534" (for D.O.). D.O. is a Senior Scholar of the Institut Universitaire de France. All antibodies used were kindly provided by Beckman-Coulter, Marseille, France. Beckman Coulter and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners. A part of this study was funded by a grant from the Wilhelm Sander Stiftung (2015.145.1) to EPvS.

Original article: Oncotarget. 2017; 8:49548–49563. <https://doi.org/10.18632/oncotarget.17747>